- Home
- PDD vs GSK Comparison
PDD vs GSK Comparison
Compare PDD & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PDD | GSK |
|---|---|---|
| Founded | 2015 | 1715 |
| Country | Ireland | United Kingdom |
| Employees | N/A | 66841 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.5B | 108.7B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | PDD | GSK |
|---|---|---|
| Price | $85.07 | $51.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 2 |
| Target Price | ★ $139.22 | N/A |
| AVG Volume (30 Days) | ★ 9.4M | 3.2M |
| Earning Date | 05-26-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 3.40% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.35 | $6.99 |
| Revenue Next Year | $12.63 | $4.19 |
| P/E Ratio | ★ $10.63 | $32.75 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $81.56 | $35.45 |
| 52 Week High | $139.41 | $61.70 |
Technical Indicators
Market Signals| Indicator | PDD | GSK |
|---|---|---|
| Relative Strength Index (RSI) | 36.80 | 51.52 |
| Support Level | $81.56 | $51.55 |
| Resistance Level | $106.47 | $51.79 |
| Average True Range (ATR) | 2.83 | 0.74 |
| MACD | -0.71 | 0.21 |
| Stochastic Oscillator | 21.62 | 87.71 |
Price Performance
Historical ComparisonAbout PDD PDD Holdings Inc.
PDD Holdings operates commerce businesses in over 80 countries globally. Its main operations are Pinduoduo, a social commerce platform in China, and Temu, a global e-commerce marketplace. PDD also has a community group purchase business in China. PDD has built a network of sourcing, logistics, and fulfillment capabilities that support its underlying businesses.
About GSK GSK plc (Each representing two)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.